Andrographolide protects against endothelial dysfunction and inflammatory response in rats with coronary heart

Jia Shu1, Ruizhen Huang2, Ying Tian3

  • 1Functional Inspection Division, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Insights

Andrographolide (Andro) demonstrates therapeutic potential for coronary heart disease (CHD). This study shows Andro preserves cardiac function, improves lipid profiles, and reduces inflammation in a mouse model of CHD.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Natural Products

Background:

  • Andrographolide (Andro), a compound from Andrographis, exhibits anti-inflammatory properties.
  • The role of Andro in coronary heart disease (CHD) pathogenesis and treatment remains largely unexplored.

Purpose of the Study:

  • To investigate the therapeutic effects of Andro on a mouse model of CHD.
  • To elucidate the underlying mechanisms of Andro's action in CHD.

Main Methods:

  • A mouse model of CHD was established and treated with varying doses of Andro.
  • Histological examination (HE staining), ELISA assays for serum markers, and Western blot analysis were performed.

Main Results:

  • Andro treatment preserved cardiac tissue, improved lipid profiles (TC, TG, LDL-C, HDL-C), and reduced inflammatory markers (TNF-α, MCP-1, hs-CRP, IL-1β).
  • Andro attenuated endothelial dysfunction, reduced cardiac apoptosis, and inhibited the activation of PPARα and NF-κB signaling pathways.

Conclusions:

  • Andrographolide shows significant therapeutic potential for treating coronary heart disease.
  • Andro may offer a novel medicinal strategy for CHD management by modulating inflammation and lipid metabolism.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
773
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.0K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
324